DEFA14A: Novartis to Acquire Avidity Biosciences, Q3 Results Strong

Avidity Biosciences announces its acquisition by Novartis for approximately $12 billion, plans a spin-off of its early-stage precision cardiology programs, and reports strong Q3 2025 financial results with positive clinical data.

Summary

• Novartis AG will acquire Avidity Biosciences, Inc. for a total equity value of approximately $12 billion, a transaction unanimously approved by both companies' Boards of Directors.
• Prior to the acquisition, Avidity will separate its early-stage precision cardiology programs and certain collaboration agreements into a new publicly traded company, SpinCo, which will be a wholly-owned subsidiary of Avidity until the spin-off.
• Avidity's neuroscience pipeline, including late-stage clinical programs del-zota (DMD), del-desiran (DM1), and del-brax (FSHD), will be acquired by Novartis.
• Del-zota for Duchenne muscular dystrophy (DMD44) has a clear path forward with the FDA following a pre-BLA meeting in October 2025, with BLA submission planned for 2026 for accelerated approval.
• One-year data for del-zota from EXPLORE44 and EXPLORE44-OLE trials demonstrated sustained muscle protection, meaningful improvement, and reversal of disease progression across multiple functional measures.
• The FDA granted Breakthrough Therapy designation to del-zota in July 2025.
• Enrollment for the Phase 3 HARBOR trial of del-desiran for myotonic dystrophy type 1 (DM1) was completed in July 2025, with 54-week topline data expected in the second half of 2026.
• Topline data from the FORTITUDE biomarker cohort for del-brax (FSHD) is expected in Q2 2026, and a global confirmatory Phase 3 study (FORTITUDE-3) has been initiated, with readout and regulatory submissions expected in 2028.
• Avidity reported collaboration revenue of $12.5 million for Q3 2025, primarily from a $10.0 million clinical development milestone with Eli Lilly and Company.
• Cash, cash equivalents, and marketable securities totaled approximately $1.9 billion as of September 30, 2025, which includes $651.4 million from a public offering and $185.5 million from common stock sales.

Sentiment

Score: 9

Explanation: The filing conveys a highly positive sentiment due to the significant acquisition by Novartis, strong clinical trial results for key drug candidates, FDA Breakthrough Therapy designation, and a robust cash position. While operating expenses and net loss increased, these are largely attributable to accelerated R&D for a promising pipeline now validated by a major acquisition. The strategic spin-off also aims to maximize shareholder value.

Positives

• Novartis's acquisition of Avidity for approximately $12 billion equity value represents a significant valuation and potential return for shareholders.
• The acquisition accelerates the global reach of Avidity's innovative neuroscience pipeline and AOC platform.
• Del-zota for DMD44 has a clear path forward with the FDA for accelerated approval, with BLA submission planned for 2026.
• Positive one-year clinical data for del-zota showed consistent, clinically meaningful improvements and reversal of disease progression.
• Del-zota received Breakthrough Therapy designation from the FDA in July 2025, indicating potential for expedited development and review.
• Completion of enrollment for the Phase 3 HARBOR trial for del-desiran (DM1) marks significant progress in its clinical development.
• Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Cash runway is expected to fund operations to mid-2028, providing financial stability.
• Collaboration revenues increased significantly to $12.5 million in Q3 2025 from $2.3 million in Q3 2024, driven by a $10.0 million milestone payment from Eli Lilly.

Negatives

• Net loss for Q3 2025 increased to $174.4 million, compared to $80.4 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $447.5 million, compared to $220.0 million for the same period in 2024.
• Research and development expenses significantly increased to $154.9 million in Q3 2025 from $77.2 million in Q3 2024, driven by advancement of clinical programs and higher manufacturing costs.
• General and administrative expenses increased to $46.3 million in Q3 2025 from $23.3 million in Q3 2024, due to higher personnel and commercial infrastructure costs.

Risks

• The timing of the satisfaction of customary closing conditions for the merger, including regulatory approvals and stockholder approval, may not be met on the expected timetable or at all.
• Risks and costs related to the implementation of the SpinCo separation, including the ability to complete it in the anticipated timeframe or at all, and potential changes to the configuration of the businesses.
• The sale of certain SpinCo assets may be subject to a third-party right of first negotiation.
• There is a risk that competing offers or acquisition proposals for Avidity will be made.
• Disruption from the transactions and their announcement may impact Novartis's and/or Avidity's businesses, including relationships with employees, business partners, or governmental entities.
• The transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Management's attention may be diverted from ongoing business operations and opportunities due to the transactions.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data, could affect product success.
• Regulatory actions or delays or government regulation generally could impact product development and approval.
• There is no guarantee that investigational products will be submitted or approved for sale or additional indications, or that the AOC platform will produce commercially valuable products.

Future Outlook

The company expects the acquisition by Novartis to close in the first half of 2026, following the separation of SpinCo. BLA submission for del-zota is planned for 2026 for accelerated approval. Topline data from the HARBOR study for del-desiran is expected in the second half of 2026, and for the FORTITUDE biomarker cohort for del-brax in Q2 2026. Global regulatory submissions for del-brax are anticipated in 2028. The company projects its current cash, cash equivalents, and marketable securities will fund operations until mid-2028.

Management Comments

• "In October, we announced that Avidity entered into a definitive merger agreement with Novartis, which we believe maximizes value for our investors, accelerates the global reach of our innovative neuroscience pipeline, and advances even more possibilities for our innovative science."
• "This important transaction, alongside compelling del-zota data and a successful pre-BLA meeting with the FDA in the third quarter, underscores the remarkable consistency of our AOC platform and the significant potential of del-zota, del-desiran, and del-brax to transform outcomes for people living with serious rare diseases."
• "These achievements are possible because of our incredibly talented Avidity team and the close collaboration of the dedicated patient and clinical communities we serve."

Industry Context

The acquisition of Avidity Biosciences by a pharmaceutical giant like Novartis highlights the increasing value placed on innovative RNA therapeutics and targeted delivery platforms in the biotech industry. This transaction allows Novartis to expand its neuroscience pipeline with late-stage clinical assets, while Avidity's strategic spin-off of its early-stage precision cardiology programs into a new public entity (SpinCo) is a common strategy to unlock value for distinct therapeutic areas and allow focused development. The positive clinical data for Avidity's AOC platform, particularly the Breakthrough Therapy designation for del-zota, reinforces the potential of this novel class of therapeutics to address rare muscle diseases, attracting significant interest from larger players seeking to bolster their portfolios with cutting-edge technologies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive consideration for their Avidity shares from Novartis and potentially shares in the new SpinCo, subject to the spin-off mechanism (pro rata distribution or sale to a third party). They will also vote on the merger.
• Employees: The acquisition by Novartis and the formation of SpinCo will likely lead to organizational changes, potentially impacting roles and reporting structures within both the acquired Avidity entity and the new SpinCo.
• Customers/Patients: The acquisition by Novartis is expected to accelerate the global reach of Avidity's neuroscience pipeline, potentially bringing new RNA therapeutics to patients with rare muscle diseases more quickly.
• Collaboration Partners: The spin-off includes certain assets that trigger a right of first negotiation with an existing collaboration partner, indicating potential changes or renegotiations for those agreements.

Next Steps

• Avidity and Novartis intend to file relevant documents with the SEC, including preliminary and definitive proxy statements, in connection with the Spin-Off and Merger.
• The definitive proxy statement and proxy card will be delivered to Avidity stockholders in advance of a special meeting relating to the transactions.
• Completion of the separation of SpinCo from Avidity is required before the acquisition closes.
• The acquisition by Novartis is expected to close in the first half of 2026, subject to customary closing conditions.
• BLA submission for del-zota for accelerated approval is planned for 2026.
• Publication of data analyses from the completed Phase 1/2 MARINA trial for del-desiran is expected in Q4 2025.
• 54-week topline data readout from the global Phase 3 HARBOR study for del-desiran is expected in the second half of 2026.
• Topline data from the FORTITUDE biomarker cohort for del-brax is expected in Q2 2026.
• Global, confirmatory Phase 3 study, FORTITUDE-3, for del-brax has been initiated.
• Phase 3 FORTITUDE-3 readout and global regulatory submissions for del-brax are expected in 2028.

Key Dates

Recommendation

The announcement of Novartis's acquisition of Avidity Biosciences for approximately $12 billion represents a substantial premium and validation of Avidity's AOC platform and pipeline. This, combined with strong positive clinical data for del-zota, its Breakthrough Therapy designation, and a clear regulatory path, significantly de-risks the investment. The planned spin-off of cardiology assets also aims to unlock additional value for shareholders. While there are increased operating expenses and net losses, these are typical for a biotech company advancing multiple late-stage programs, and the acquisition mitigates the financial burden and future capital needs. The current market price, if below the acquisition value, presents a strong buying opportunity for investors seeking to capitalize on the merger arbitrage and the potential of the SpinCo.

Keywords

Avidity Biosciences, Novartis, Acquisition, Spin-Off, RNA Therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Duchenne Muscular Dystrophy, DMD, Myotonic Dystrophy Type 1, DM1, Facioscapulohumeral Muscular Dystrophy, FSHD, del-zota, del-desiran, del-brax, Biopharmaceutical, Clinical Trials, FDA Breakthrough Therapy, Merger Agreement, Q3 Earnings